{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116754","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.313016+00:00","generated_at":"2026-06-08T05:57:54.906638+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Theriva reports Q3 2023 cash of $31.2M, VCN-01 trial on track for H1 2024 enrollment completion","bullets":["Cash and equivalents $31.2M as of Sept 30, 2023; expected runway into Q1 2025.","R&D expense $4.0M in Q3 2023, up 56% from $2.6M YoY, driven by VCN-01 clinical costs.","VIRAGE Phase 2b trial of VCN-01 in metastatic PDAC remains on track to complete enrollment in H1 2024.","Meeting with FDA before year-end to discuss VCN-01 development pathway for pediatric retinoblastoma.","SYN-004 Phase 1b/2a trial in HCT recipients on track for second cohort enrollment in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116754","json":"https://secwatch.observer/filing/0001104659-23-116754.json","markdown":"https://secwatch.observer/filing/0001104659-23-116754.md","text":"https://secwatch.observer/filing/0001104659-23-116754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/0001104659-23-116754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/tm2330262d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:57:54.906638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33bda1a76dcc9a5b21e8541e73c4268878d77195","claim":"Theriva Biologics, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/0001104659-23-116754-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}